EP
VYGR icon

Essential Partners’s Voyager Therapeutics VYGR Stock Holding History

Essential Partners’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$886 Sell
253
-233
-48% -$884 ﹤0.01% 2290
2026
Q1 		$1.88K Buy
486
+212
+77% +$835 ﹤0.01% 2033
2025
Q4 		$1.08K Buy
274
+4
+1% +$18 ﹤0.01% 2008
2025
Q3 		$1.26K Buy
270
+225
+500% +$814 ﹤0.01% 1952
2025
Q2 		$140 Buy
+45
New +$145 ﹤0.01% 2020

Other funds holding VYGR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Essential Partners's VYGR Position: Q2 2026 in Review

Essential Partners reduced its Voyager Therapeutics (VYGR) stake by 48% in Q2 2026, selling an estimated $884 and leaving 253 shares worth $886. The position accounts for ﹤0.01% of the portfolio, ranked #2290.

Essential Partners first reported a position in VYGR in Q2 2025 and has held it in 5 quarters since. The position peaked at $1.88K in Q1 2026. 135 funds tracked by Wall St. Rank hold VYGR as of Q2 2026.

  • Essential Partners held 253 shares of Voyager Therapeutics worth $886 as of Q2 2026.
  • Essential Partners sold 233 Voyager Therapeutics shares in Q2 2026, an estimated $884.
  • Voyager Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2290 holding.
  • Essential Partners first reported a position in Voyager Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Essential Partners's Voyager Therapeutics position peaked at $1.88K in Q1 2026.
  • 135 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.